Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder.
Saved in:
| Title: | Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder. |
|---|---|
| Authors: | Shulman, Matisyahu, Greiner, Miranda, Bisaga, Adam |
| Source: | Addiction. Jan2024, Vol. 119 Issue 1, p158-159. 2p. |
| Subjects: | Controlled release drugs, Naltrexone, Substance abuse, Central nervous system stimulants, Narcotic antagonists, Buprenorphine, Disease relapse, Risk assessment, Methamphetamine, Amphetamines, Cocaine, Drugs of abuse, Disease risk factors |
| Abstract: | The authors comment on a secondary analysis by C. Foot et al on clinical considerations in addressing comorbid stimulant use in opioid use disorder. Topics include effective medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid use disorder, evidence for the use of a prescription stimulant in extended-release formulation to treat methamphetamine use disorder, and the need for further research to guide clinicians in the treatment of high-risk population. |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The authors comment on a secondary analysis by C. Foot et al on clinical considerations in addressing comorbid stimulant use in opioid use disorder. Topics include effective medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid use disorder, evidence for the use of a prescription stimulant in extended-release formulation to treat methamphetamine use disorder, and the need for further research to guide clinicians in the treatment of high-risk population. |
|---|---|
| ISSN: | 09652140 |
| DOI: | 10.1111/add.16374 |
